The Saudi Food and Drug Authority announced that its CEO, Dr. Hisham S. Aljadhey, met with Dr. Oh Yu-kyoung, South Korea’s Minister of Food and Drug Safety, on the sidelines of the International Coalition of Medicines Regulatory Authorities Summit in Seoul. The discussions reviewed existing cooperation under a memorandum of understanding signed in 2023 that targets higher standards of quality and safety across food, pharmaceuticals and medical products. Officials from both sides examined ways to build on that framework through practical collaboration.
According to the SFDA, the two parties explored opportunities for joint scientific evaluation of drugs along with the exchange of expertise in food monitoring and traceability systems. The authority’s statement added that the talks covered approaches to managing risks from foodborne illnesses, including prevention methods and ways to reduce their incidence through shared best practices. These exchanges aim to improve regulatory effectiveness in both countries.
Representatives from the Saudi Halal Center participated in the meeting alongside a South Korean technical team specializing in food-transmitted diseases, the SFDA reported. The presence of these experts allowed for targeted dialogue on halal-related regulatory matters. Such inclusion highlights the breadth of issues addressed during the session.
The SFDA detailed that Dr. Aljadhey also held separate bilateral meetings with regulatory heads from Egypt, Portugal, the United Kingdom, Singapore and Japan during the same summit. Those conversations focused on topics of mutual interest, strengthening cooperation and facilitating knowledge exchange in regulatory fields. The multiple engagements demonstrate the authority’s commitment to international partnerships.
A related SFDA initiative the day before the main meeting saw Dr. Aljadhey convene with executives from leading South Korean biotech companies to discuss cooperation in biotechnology and advanced therapies. That roundtable, held in the presence of Saudi Commercial Attaché Saeed Almadani, reviewed the authority’s updated regulatory pathways for innovative treatments. Discussions emphasized alignment with Saudi Arabia’s National Biotechnology Strategy.
The 2023 memorandum between the SFDA and South Korea’s ministry has laid groundwork for ongoing work that supports broader bilateral ties, according to the authority. South Korea’s regulatory experience in these sectors complements Saudi efforts to enhance health safeguards and facilitate trade in regulated products. The SFDA continues to pursue similar agreements with other nations to advance its objectives.
ع